Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.
The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.
Intellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。